Package Leaflet: Information for the User
Feoxan 200 mg EFG tablets
Feoxan 400 mg EFG tablets
Feoxan 800 mg EFG tablets
eslicarbazepine acetate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Feoxan contains the active substance eslicarbazepine acetate.
Eslicarbazepine belongs to a group of medicines called antiepileptics, used to treat epilepsy, a condition where the person has repeated seizures or fits.
Eslicarbazepine is used:
Your doctor has prescribed eslicarbazepine to reduce the number of seizures.
Do not take Feoxan:
Warnings and precautions
Talk to your doctor or pharmacist before you start taking eslicarbazepine.
Tell your doctor immediately:
Tell your doctor:
A small number of people taking antiepileptics have had thoughts of harming themselves or suicidal thoughts. If at any time you have these thoughts, contact your doctor immediately.
Eslicarbazepine may make you feel dizzy and/or drowsy, particularly at the start of treatment. Be particularly careful while taking eslicarbazepine to avoid accidental injury, such as falls.
Be particularly careful with eslicarbazepine.
In post-marketing experience, in patients treated with eslicarbazepine, serious and potentially life-threatening skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported.
If you develop a severe rash or other skin symptom (see section 4), stop taking eslicarbazepine and contact your doctor or seek medical attention immediately.
In Thai and Chinese Han ethnic patients, the risk of serious skin reactions associated with carbamazepine or chemically related compounds can be predicted by a blood test in these patients. Your doctor will advise you on the need for such a blood test before taking eslicarbazepine.
Children
Eslicarbazepine should not be given to children under 6 years of age.
Taking Feoxan with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because some medicines may affect the way eslicarbazepine works, or eslicarbazepine may affect the way other medicines work. Tell your doctor if you are taking:
See the section “Pregnancy and breast-feeding” for recommendations on contraception.
Pregnancy and breast-feeding
Eslicarbazepine acetate should not be used during pregnancy, as its effects on pregnancy and the unborn child are not known.
If you are planning to become pregnant, talk to your doctor before stopping your contraceptive method and before becoming pregnant. Your doctor may decide to change your treatment.
There is limited data on the use of eslicarbazepine acetate in pregnant women.
Studies have shown an increased risk of congenital malformations and neurodevelopmental problems (brain development) in children of women taking antiepileptic medicines, particularly when taking more than one antiepileptic medicine at the same time.
If you are pregnant or think you may be pregnant, tell your doctor immediately. Do not stop taking your medicine until you have talked to your doctor. Stopping your medicine suddenly may cause seizures, which could be harmful for you and your unborn child. Your doctor may decide to change your treatment.
If you are a woman of childbearing age and not planning to become pregnant, you should use an effective method of contraception during treatment with eslicarbazepine acetate. Eslicarbazepine acetate may affect the effectiveness of hormonal contraceptives, such as the pill, and make them less effective in preventing pregnancy. Therefore, you are advised to use other safe and effective methods of contraception while taking eslicarbazepine. Talk to your doctor, who will discuss with you the most suitable type of contraception to use while taking eslicarbazepine acetate. If you stop taking eslicarbazepine acetate, you should continue to use an effective method of contraception until the end of your current menstrual cycle. If you take eslicarbazepine acetate during pregnancy, your baby is at risk of bleeding problems immediately after birth. Your doctor may give you and your baby a medicine to prevent this.
Do not breast-feed while taking eslicarbazepine acetate. It is not known if it passes into breast milk.
Driving and using machines
Eslicarbazepine may cause dizziness, drowsiness and affect your vision, particularly at the start of treatment. If this happens to you, do not drive or use any tools or machines.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Adults
Dose at the start of treatment
400 mg once a day for one or two weeks, before increasing to the maintenance dose. Your doctor will decide whether you should be given this dose for one or two weeks.
Maintenance dose
The usual maintenance dose is 800 mg once a day.
Depending on how you respond to eslicarbazepine, the dose may be increased to 1,200 mg once a day. If you are taking eslicarbazepine only (monotherapy), your doctor may consider increasing the dose to 1,600 mg once a day.
Patient with kidney problems
If you have kidney problems, you will usually be given a lower dose of eslicarbazepine. Your doctor will determine the correct dose for you. Eslicarbazepine is not recommended if you have severe kidney disease.
Elderly patients (above 65 years of age)
If you are an elderly patient and are taking eslicarbazepine in monotherapy, the dose of 1,600 mg is not suitable for you.
Children over 6 years of age
Dose at the start of treatment
The starting dose is 10 mg per kg of body weight once a day for one or two weeks, before increasing to the maintenance dose.
Maintenance dose
Depending on the response to eslicarbazepine, the dose may be increased by 10 mg per kg of body weight, at intervals of one or two weeks, up to 30 mg per kg of body weight. The maximum dose is 1,200 mg once a day.
Children ≥ 60 kg
Children with a body weight of 60 kg or more should take the same dose as adults.
The oral suspension, another pharmaceutical form of the medicine, may be more suitable for administration in children. Talk to your doctor or pharmacist.
Form and route of administration
Eslicarbazepine is taken by mouth. Swallow the tablet with a glass of water. Eslicarbazepine can be taken with or without food.
If you take more Feoxan than you should
If you accidentally take more eslicarbazepine than you should, you are at risk of having more seizures; or you may feel that your heart is beating irregularly or faster. Contact your doctor or go immediately to a hospital if you experience any of these symptoms. Take the medicine package with you, so that the doctor knows what you have taken.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Feoxan
If you forget to take a tablet, take it as soon as you remember and then continue as normal. Do not take a double dose to make up for forgotten doses.
If you stop taking Feoxan
Do not stop taking the tablets suddenly. If you do, you are at risk of having more seizures. Your doctor will decide how long you should take eslicarbazepine. If your doctor decides to stop your treatment with eslicarbazepine, your dose will usually be reduced gradually. It is important that you complete the treatment as your doctor has told you; otherwise, your symptoms may get worse.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
The following adverse effects can be very serious. If they appear, discontinue the administration of eslicarbazepine and inform a doctor or go to a hospital immediately, as urgent medical treatment may be needed:
Very common adverse effects (may affect more than 1 in 10 people) are:
Common adverse effects (may affect up to 1 in 10 people) are:
Uncommon adverse effects (may affect up to 1 in 100 people) are:
Adverse effects of unknown frequency (cannot be estimated from available data) are:
/
The use of eslicarbazepine is associated with an ECG (electrocardiogram) anomaly called an increased PR interval. Adverse effects associated with this ECG anomaly (e.g., fainting and slowing of heartbeats) may occur.
Bone disorders, including osteopenia and osteoporosis (thinning of the bones), and fractures have been reported with structurally related antiepileptic medications, such as carbamazepine and oxcarbazepine. Talk to your doctor or pharmacist if you are on long-term treatment with antiepileptics, have a history of osteoporosis, or take steroids.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Medicines Monitoring System: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the blister, bottle, and carton after the letters CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Feoxan
Feoxan 200 mg: each tablet contains 200 mg of eslicarbazepine acetate.
Feoxan 400 mg: each tablet contains 400 mg of eslicarbazepine acetate.
Feoxan 800 mg: each tablet contains 800 mg of eslicarbazepine acetate.
Appearance of the Product and Package Contents
The Feoxan 200 mg tablets are white to off-white, oblong, and biconvex, scored on both sides, with an approximate length of 11.8 mm and an approximate thickness of 3.9 mm. The tablet can be divided into equal doses.
The Feoxan 400 mg tablets are white to off-white, oblong, and biconvex, scored on both sides, with an approximate length of 15.0 mm and an approximate thickness of 4.9 mm. The tablet can be divided into equal doses.
The Feoxan 800 mg tablets are white to off-white, oblong, and biconvex, scored on both sides, with an approximate length of 18.9 mm and an approximate thickness of 6.1 mm. The tablet can be divided into equal doses.
The tablets are packaged in transparent or opaque blisters, boxed in cardboard boxes of 20, 28, 30, 60, or 90 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
info@stada.es
Manufacturer
G.L. Pharma GmbH
Schlossplatz 1
8502 Lannach
Austria
or
Delorbis Pharmaceuticals Ltd.
17 Athinon Street
Ergates Industrial Area 2643 Ergates
2081 Lefkosia
Cyprus
or
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
Date of the Last Revision of this Prospectus:June 2019
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of FEOXAN 400 mg TABLETS in October, 2025 is around 42.96 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.